Recommendations for AbbVie’s Overdependence on Humira
Patent Cliff and AbbVie Patent Cliff, referred as drop in sales after the patent expires, is a global revenue threat to major pharmaceutical companies. Around 45% revenue dependence on a single medicine, Humira, by AbbVie is quite high in comparison with the industry, and the company can face major drop in revenue after the year 2016. As this product is currently a hit in the market, there are already many companies who have developed a biosimiliar of this medicine. These biosimiliars will be launched in the market after the patent expiry in 2016. Apart from major drop in revenue, the company is ...
